Atezolizumab Plus Bevacizumab and Chemotherapy in Nonsquamous Lung Cancer
Posted: Thursday, May 24, 2018
The addition of atezolizumab to bevacizumab with chemotherapy provided an advantage in progression-free survival over the combination therapy without atezolizumab for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The findings of the IMpower150 trial were presented at the 2018 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago (Abstract CT076). The study, conducted by Mark A. Socinski, MD, of the Florida Hospital Cancer Institute, Orlando, observed this clinical benefit across all PD-L1 subgroups, regardless of the immunohistochemistry assay used.
“Additionally, clinically meaningful [progression-free survival] benefit was observed in patients with EGFR/ALK genomic alterations and in patients with liver metastases with this combination,” the investigators commented.
Patients received one of two regimens: 1,200 mg of atezolizumab, 15 mg/kg of bevacizumab, carboplatin AUC 6, and 200 mg/m2 of paclitaxel (Arm B), or bevacizumab, carboplatin, and paclitaxel intravenously every 3 weeks (Arm C).
For both groups in the intention-to-treat wild-type (ITT-WT) population, 503 of 692 had available tumor sections for SP263 testing (BEP). In the ITT-WT group, a median progression-free survival of 8.3 months was observed in Arm B and 6.8 months in Arm C, with the same progression-free survival noted in the BEP group. A benefit in progression-free survival was also observed in Arm B versus Arm C across all PD-L1–expression subgroups, including patients with PD-L1–negative and PD-L1–low tumors.
